155 related articles for article (PubMed ID: 38527265)
1. Tumor-Infiltrating Lymphocyte and Other Cell Therapies for Metastatic Melanoma.
Los C; Klobuch S; Haanen JBAG
Cancer J; 2024 Mar-Apr 01; 30(2):113-119. PubMed ID: 38527265
[TBL] [Abstract][Full Text] [Related]
2. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
Wu R; Forget MA; Chacon J; Bernatchez C; Haymaker C; Chen JQ; Hwu P; Radvanyi LG
Cancer J; 2012; 18(2):160-75. PubMed ID: 22453018
[TBL] [Abstract][Full Text] [Related]
3. Adoptive T-cell transfer in melanoma.
Itzhaki O; Levy D; Zikich D; Treves AJ; Markel G; Schachter J; Besser MJ
Immunotherapy; 2013 Jan; 5(1):79-90. PubMed ID: 23256800
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
Chesney J; Lewis KD; Kluger H; Hamid O; Whitman E; Thomas S; Wermke M; Cusnir M; Domingo-Musibay E; Phan GQ; Kirkwood JM; Hassel JC; Orloff M; Larkin J; Weber J; Furness AJS; Khushalani NI; Medina T; Egger ME; Graf Finckenstein F; Jagasia M; Hari P; Sulur G; Shi W; Wu X; Sarnaik A
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600653
[TBL] [Abstract][Full Text] [Related]
5. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
6. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma.
Yeh S; Karne NK; Kerkar SP; Heller CK; Palmer DC; Johnson LA; Li Z; Bishop RJ; Wong WT; Sherry RM; Yang JC; Dudley ME; Restifo NP; Rosenberg SA; Nussenblatt RB
Ophthalmology; 2009 May; 116(5):981-989.e1. PubMed ID: 19410956
[TBL] [Abstract][Full Text] [Related]
7. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.
Chandran SS; Somerville RPT; Yang JC; Sherry RM; Klebanoff CA; Goff SL; Wunderlich JR; Danforth DN; Zlott D; Paria BC; Sabesan AC; Srivastava AK; Xi L; Pham TH; Raffeld M; White DE; Toomey MA; Rosenberg SA; Kammula US
Lancet Oncol; 2017 Jun; 18(6):792-802. PubMed ID: 28395880
[TBL] [Abstract][Full Text] [Related]
8. Predictors of tumor-infiltrating lymphocyte efficacy in melanoma.
Zikich D; Schachter J; Besser MJ
Immunotherapy; 2016; 8(1):35-43. PubMed ID: 26653685
[TBL] [Abstract][Full Text] [Related]
9. Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.
Ascierto PA; Agarwala SS; Ciliberto G; Demaria S; Dummer R; Duong CPM; Ferrone S; Formenti SC; Garbe C; Halaban R; Khleif S; Luke JJ; Mir LM; Overwijk WW; Postow M; Puzanov I; Sondel P; Taube JM; Thor Straten P; Stroncek DF; Wargo JA; Zarour H; Thurin M
J Transl Med; 2017 Nov; 15(1):236. PubMed ID: 29145885
[TBL] [Abstract][Full Text] [Related]
10. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
Rohaan MW; Borch TH; van den Berg JH; Met Ö; Kessels R; Geukes Foppen MH; Stoltenborg Granhøj J; Nuijen B; Nijenhuis C; Jedema I; van Zon M; Scheij S; Beijnen JH; Hansen M; Voermans C; Noringriis IM; Monberg TJ; Holmstroem RB; Wever LDV; van Dijk M; Grijpink-Ongering LG; Valkenet LHM; Torres Acosta A; Karger M; Borgers JSW; Ten Ham RMT; Retèl VP; van Harten WH; Lalezari F; van Tinteren H; van der Veldt AAM; Hospers GAP; Stevense-den Boer MAM; Suijkerbuijk KPM; Aarts MJB; Piersma D; van den Eertwegh AJM; de Groot JB; Vreugdenhil G; Kapiteijn E; Boers-Sonderen MJ; Fiets WE; van den Berkmortel FWPJ; Ellebaek E; Hölmich LR; van Akkooi ACJ; van Houdt WJ; Wouters MWJM; van Thienen JV; Blank CU; Meerveld-Eggink A; Klobuch S; Wilgenhof S; Schumacher TN; Donia M; Svane IM; Haanen JBAG
N Engl J Med; 2022 Dec; 387(23):2113-2125. PubMed ID: 36477031
[TBL] [Abstract][Full Text] [Related]
11. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M
Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262
[TBL] [Abstract][Full Text] [Related]
12. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
Sarnaik AA; Hamid O; Khushalani NI; Lewis KD; Medina T; Kluger HM; Thomas SS; Domingo-Musibay E; Pavlick AC; Whitman ED; Martin-Algarra S; Corrie P; Curti BD; Oláh J; Lutzky J; Weber JS; Larkin JMG; Shi W; Takamura T; Jagasia M; Qin H; Wu X; Chartier C; Graf Finckenstein F; Fardis M; Kirkwood JM; Chesney JA
J Clin Oncol; 2021 Aug; 39(24):2656-2666. PubMed ID: 33979178
[TBL] [Abstract][Full Text] [Related]
13. Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma.
Seitter SJ; Sherry RM; Yang JC; Robbins PF; Shindorf ML; Copeland AR; McGowan CT; Epstein M; Shelton TE; Langhan MM; Franco Z; Danforth DN; White DE; Rosenberg SA; Goff SL
Clin Cancer Res; 2021 Oct; 27(19):5289-5298. PubMed ID: 34413159
[TBL] [Abstract][Full Text] [Related]
14. Adoptive Cell Therapy for Metastatic Melanoma.
Merhavi-Shoham E; Itzhaki O; Markel G; Schachter J; Besser MJ
Cancer J; 2017; 23(1):48-53. PubMed ID: 28114254
[TBL] [Abstract][Full Text] [Related]
15. Adoptive tumor infiltrating lymphocyte transfer as personalized immunotherapy.
Diaz-Cano I; Paz-Ares L; Otano I
Int Rev Cell Mol Biol; 2022; 370():163-192. PubMed ID: 35798505
[TBL] [Abstract][Full Text] [Related]
16. Rapid complete remission of metastatic melanoma after first-line treatment with nivolumab plus tumor-infiltrating lymphocytes.
Zhao L; Yang Y; Li W; Han L; Lin H; Gao Q
Immunotherapy; 2018 Sep; 10(13):1133-1136. PubMed ID: 30236024
[TBL] [Abstract][Full Text] [Related]
17. Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development.
Sim GC; Chacon J; Haymaker C; Ritthipichai K; Singh M; Hwu P; Radvanyi L
BioDrugs; 2014 Oct; 28(5):421-37. PubMed ID: 24890028
[TBL] [Abstract][Full Text] [Related]
18. Adoptive cell transfer therapy for melanoma.
Inozume T
Exp Dermatol; 2023 Mar; 32(3):250-255. PubMed ID: 36382355
[TBL] [Abstract][Full Text] [Related]
19. Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma.
Borch TH; Andersen R; Ellebaek E; Met Ö; Donia M; Svane IM
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32747469
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.
Saberian C; Amaria RN; Najjar AM; Radvanyi LG; Haymaker CL; Forget MA; Bassett RL; Faria SC; Glitza IC; Alvarez E; Parshottam S; Prieto V; Lizée G; Wong MK; McQuade JL; Diab A; Yee C; Tawbi HA; Patel S; Shpall EJ; Davies MA; Hwu P; Bernatchez C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
